Nair, Ajay Kumar;
Van Hulle, Carol A;
Bendlin, Barbara B;
Zetterberg, Henrik;
Blennow, Kaj;
Wild, Norbert;
Kollmorgen, Gwendlyn;
... Rosenkranz, Melissa A; + view all
(2022)
Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline.
Alzheimer's and Dementia: Translational Research and Clinical Interventions
, 8
(1)
, Article e12315. 10.1002/trc2.12315.
Preview |
PDF
A D Transl Res Clin Interv - 2022 - Nair.pdf - Published Version Download (1MB) | Preview |
Abstract
Introduction: Evidence from epidemiology, neuroimaging, and animal models indicates that asthma adversely affects the brain, but the nature and extent of neuropathophysiological impact remain unclear. Methods: We tested the hypothesis that asthma is a risk factor for dementia by comparing cognitive performance and cerebrospinal fluid biomarkers of glial activation/neuroinflammation, neurodegeneration, and Alzheimer's disease (AD) pathology in 60 participants with asthma to 315 non-asthma age-matched control participants (45-93 years), in a sample enriched for AD risk. Results: Participants with severe asthma had higher neurogranin concentrations compared to controls and those with mild asthma. Positive relationships between cardiovascular risk and concentrations of neurogranin and α-synuclein were amplified in severe asthma. Severe asthma also amplified the deleterious associations that apolipoprotein E ε4 carrier status, cardiovascular risk, and phosphorylated tau181/amyloid beta42 have with rate of cognitive decline. Discussion: Our data suggest that severe asthma is associated with synaptic degeneration and may compound risk for dementia posed by cardiovascular disease and genetic predisposition. Highlights: Those with severe asthma showed evidence of higher dementia risk than controls evidenced by: higher levels of the synaptic degeneration biomarker neurogranin regardless of cognitive status, cardiovascular or genetic risk, and controlling for demographics.steeper increase in levels of synaptic degeneration biomarkers neurogranin and α-synuclein with increasing cardiovascular risk.accelerated cognitive decline with higher cardiovascular risk, genetic predisposition, or pathological tau.
| Type: | Article |
|---|---|
| Title: | Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/trc2.12315 |
| Publisher version: | https://doi.org/10.1002/trc2.12315 |
| Language: | English |
| Additional information: | © 2022 The Authors. Alzheimer’s & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals, LLC on behalf of Alzheimer’s Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| Keywords: | Alzheimer's disease, asthma, cerebrospinal fluid biomarkers, cognition, comorbidities, dementia, glial activation, neurodegeneration, neuroinflammation, synaptic dysfunction cognition |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10154016 |
Archive Staff Only
 |
View Item |
